EP Patent

EP1477175A1 — Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient

Assigned to Ono Pharmaceutical Co Ltd · Expires 2004-11-17 · 21y expired

What this patent protects

Fused pyridazine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof (wherein each symbol has the meaning as defined in the specification.). Because of inhibiting poly(ADP-ribose)polymerase, the compounds represented by formula (I) are useful as …

USPTO Abstract

Fused pyridazine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof (wherein each symbol has the meaning as defined in the specification.). Because of inhibiting poly(ADP-ribose)polymerase, the compounds represented by formula (I) are useful as preventives and/or remedies for various ischemic diseases (in brain, cord, heart, digestive tract, skeletal muscle, retina, etc. ), inflammatory diseases (inflammatory bowel disease, multiple cerebrosclerosis, arthritis, etc .), neurodegenerative diseases (extrapyramidal disorder, Alzheimer's disease, muscular dystrophy, lumbar spinal canal stenosis, etc. ), diabetes, shock, head trauma, renal failure, hyperalgesia, etc . Moreover, these compounds are useful as agents against retroviruses (HIV etc. ), sensitizers in treating cancer and immunosuppressants.

Drugs covered by this patent

Patent Metadata

Patent number
EP1477175A1
Jurisdiction
EP
Classification
Expires
2004-11-17
Drug substance claim
No
Drug product claim
No
Assignee
Ono Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.